CHELSEA VALENZIANO: Open Payments
NPI 1710737523 · STEELTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,471 in 132 payments from 26 companies in 2025. Trend: 2023 $0 · 2024 $377 · 2025 $2,471
Food & beverage: $2,471
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $440 |
| Novo Nordisk Inc | 18 | $236 |
| GlaxoSmithKline, LLC. | 12 | $217 |
| Lilly USA, LLC | 11 | $216 |
| AstraZeneca Pharmaceuticals LP | 6 | $185 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $149 |
| Dexcom, Inc. | 6 | $114 |
| Exact Sciences Corporation | 4 | $103 |
| Amgen Inc. | 5 | $86 |
Products named: JARDIANCE, UBRELVY, MOUNJARO, VRAYLAR, CAPLYTA, TRELEGY ELLIPTA, QULIPTA, Wegovy.
Industry payments across PA — which companies pay providers there.
